[Antibacterial activity of norfloxacin and pipemidic acid in a randomized double-blind study].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D001437:Bacteriuria / Q000188:drug therapy / Q000382:microbiology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006090:Gram-Negative Bacteria / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000627:therapeutic use*; D009643:Norfloxacin; D010876:Pipemidic Acid / Q000627:therapeutic use*; D011897:Random Allocation; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology
D000892:Anti-Infective Agents, Urinary; D009539:Nicotinic Acids; D009268:Nalidixic Acid; D010876:Pipemidic Acid; D009643:Norfloxacin
Attività antibatterica della Norfloxacina e dell'Acido pipemidico in uno studio randomizzato a doppio cieco.